source
- Study finds Lilly's obesity drug Zepbound may lower hospital and ER costs for older adultsA real‑world analysis examined older patients with obesity or excess weight who were either treated with Eli Lilly’s drug Zepbound or not. The researchers tracked healthcare utilization over time t…
- Akeso reports phase 3 overall survival win for ivonescimab in advanced biliary tract cancerAkeso announced that its bispecific antibody ivonescimab combined with chemotherapy improved overall survival in a China phase 3 trial for advanced biliary tract cancer, beating the standard regime…